John A. Copland

Jacksonville College

Full Professor(heuristic)

Cancer, Lipids, and Metabolism · Cancer Research

Compare more Cancer Research professors.

h-index71
i10-index157
Publications424
Citations49,031

Grants

7 total · 0 active

NIH #R44CA272064

Modulation of cancer induced immune suppression via inhibition of SCD1

Amount
$1M–$2M
Period
2022-09-15 → 2025-08-31
PIs
3

Awarded at MODULATION THERAPEUTICS, INC.

NIH #R01CA251443

Engineered microtumor arrays for development of combination therapies

Amount
$200K–$300K
Period
2020-09-09 → 2024-06-30
PIs
2

Awarded at UNIVERSITY OF NEW SOUTH WALES

NIH #R42CA195946

Novel SCD1 inhibitors for treatment of cancer

Amount
$1M–$2M
Period
2016-03-05 → 2022-08-31
PIs
2

Awarded at MODULATION THERAPEUTICS, INC.

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

7 total · 0 active

NIH #R44CA272064

Modulation of cancer induced immune suppression via inhibition of SCD1

Amount
$1M–$2M
Period
2022-09-15 → 2025-08-31
PIs
3

Awarded at MODULATION THERAPEUTICS, INC.

NIH #R01CA251443

Engineered microtumor arrays for development of combination therapies

Amount
$200K–$300K
Period
2020-09-09 → 2024-06-30
PIs
2

Awarded at UNIVERSITY OF NEW SOUTH WALES

NIH #R42CA195946

Novel SCD1 inhibitors for treatment of cancer

Amount
$1M–$2M
Period
2016-03-05 → 2022-08-31
PIs
2

Awarded at MODULATION THERAPEUTICS, INC.

NIH #R41CA210669

Osteopontin-targeted therapy for primary CNS lymphoma

Amount
$200K–$300K
Period
2017-08-28 → 2019-07-31
PIs
2

Awarded at MODULATION THERAPEUTICS, INC.

NIH #R41CA195946

Novel SCD1 inhibitors for treatment of cancer

Amount
$200K–$300K
Period
2016-03-05 → 2017-08-31
PIs
2

Awarded at MODULATION THERAPEUTICS, INC.

NIH #R01CA136665

RhoB in cancer pathogenesis and as a target in combinatorial therapy

Amount
$300K–$400K
Period
2010-07-01 → 2015-04-30
PIs
2

Awarded at MAYO CLINIC JACKSONVILLE

NIH #R01CA104505

TGF Beta receptor biology in human renal cell carcinoma

Amount
$300K–$400K
Period
2004-08-10 → 2009-07-31
PIs
1

Awarded at MAYO CLINIC JACKSONVILLE

Recent Public Signals

  1. New paper: Supplementary Figure 1 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer2026-06-17

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-08-27

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0001-5091-6242

Professor Insights

Career Trajectory